STAT

APRIL 18, 2024

In the chaotic first few months of the Covid-19 pandemic, stores faced shortages of all kinds — toilet paper, canned food, and especially, cleaning supplies. With everyone scrubbing their groceries, mail, even library books, good luck finding antibacterial wipes or disinfectant sprays back then. That’s because public health advice in early 2020 focused on sanitizing surfaces, not protecting against a virus that could be spread through the air.

364

364

PharmaVoice

APRIL 18, 2024

As precision medicine booms, all trials are starting to look like rare disease trials, the company said.

130

130

STAT

APRIL 18, 2024

As two former secretaries of Health and Human Services, we are all too familiar with the struggle of finding narrow openings for bipartisanship. Despite our different approaches, we believe that addressing health care costs is a truly bipartisan issue. To be serious about creating access for people to the best possible care, that care must be affordable for patients and taxpayers.

363

363

BioPharma Dive

APRIL 18, 2024

It’s “early innings” in the obesity drug race, said Metsera CEO Clive Meanwell, whose company has acquired a portfolio of medicines it aims to test in combination.

127

127

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

APRIL 18, 2024

An ongoing investigation into data integrity at Dana-Farber Cancer Institute has resulted in a string of retractions, the latest of which is a 2006 Science paper co-authored by institute president and CEO Laurie Glimcher. The retraction notice, published in Science on Thursday, noted that the authors had become aware of discrepancies in key scientific images that led them to lose confidence in key figures in the study, although the study’s lead author opposed the retraction.

362

362

BioPharma Dive

APRIL 18, 2024

The start of a so-called rolling review formally begins an FDA evaluation of a closely watched drug that’s important to the biotech’s future, but faces questions about its sales potential.

122

122

pharmaphorum

APRIL 18, 2024

In a new episode of the pharmaphorum podcast, web editor Nicole Raleigh welcomes Dr Carl Marci, chief psychiatrist and managing director of mental health and neuroscience at OM1 to discuss predictions for AI in mental health in the coming year, as well as what might truly make a difference in the field and lessen the mental health crisis.

121

121

STAT

APRIL 18, 2024

A leading animal rights group has asked securities regulators to investigate Charles River Laboratories for allegedly misleading investors about its sales and purchases of long-tailed macaques, which are widely used in clinical research by pharmaceutical companies and universities, among others. The company, one of the largest clinical research organizations, was accused of failing to disclose purchases of thousands of non-human primates that should not have been imported into the U.S. and obtai

Labelling 350

Labelling Pharmaceutical Companies Pharmaceutical Companies Drug Development 350

BioPharma Dive

APRIL 18, 2024

Analysts had low expectations for Cerevel’s drug tavapadon, which was something of an afterthought in AbbVie’s proposed buyout of the biotech.

127

127

STAT

APRIL 18, 2024

A new startup focused on creating vaccines for cancers, influenza, and potentially even HIV launched Thursday with $54 million in funding. Corner Therapeutics’ Series A round was led by Ziff Capital Partners, a little-known family office started by billionaire Dirk Ziff. The biotech is also being led by Spark Therapeutics co-founder Steven Altschuler, who joined Ziff Capital in 2018 as its managing director of health care ventures.

Vaccines 340

Vaccines Hospitals 340

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

pharmaphorum

APRIL 18, 2024

Embark on an omnichannel marketing odyssey by exploring the top trends reshaping the industry in 2024. Discover how chatbots, video content, and interactivity are transforming marketing strategies.

114

114

STAT

APRIL 18, 2024

After a tumultuous experience on the public markets, 23andMe CEO Anne Wojcicki is moving to take the company private. Wojcicki disclosed her plans in a filing with the Securities and Exchange Commission late Wednesday, saying that she intends to seek out potential partners and financiers to help. Wojcicki currently holds 49.99% of the voting power in the company, according to the Wall Street Journal, which first reported on the plan.

340

340

Pharmaceutical Technology

APRIL 18, 2024

Outrun Therapeutics announced its launch with $10m seed funding to advance a protein stabilisation pipeline focused on E3 ligase inhibitors.

129

129

STAT

APRIL 18, 2024

Cerevel Therapeutics, a neuroscience biotech that AbbVie is acquiring , reported that its drug for Parkinson’s disease improved motor symptom control as an add-on therapy in a late-stage trial. The 27-week study found that patients taking the drug, tavapadon, on top of a common Parkinson’s treatment called levodopa, experienced   1.7 hours of improvement in “on time” without dyskinesia, which is the amount of time patients function well without involuntary m

329

329

pharmaphorum

APRIL 18, 2024

UK researchers describe an algorithm that is more accurate than current tools at predicting an individual’s risk of developing cardiovascular disease in the next 10 years.

110

110

STAT

APRIL 18, 2024

Each day, more than 1,000 babies are born prematurely in America. Born before 37 weeks and often weighing less than five pounds, these infants are at greater risk for a suite of serious health problems, including life-threatening infections, chronic lung disease, blindness, and death. One of the leading causes of death is necrotizing enterocolitis. An inflammatory disease of the gut, necrotizing enterocolitis can kill up to 40% of the smallest — and most vulnerable — babies.

322

322

Outsourcing Pharma

APRIL 18, 2024

Yesterday, Thermo Fisher Scientific opened its first Innovation Lab in Center Valley, Pennsylvania., as a space where partners can come together to collaborate, innovate, and ideate on solutions to the biggest clinical supply chain pain points.

106

106

STAT

APRIL 18, 2024

After scouring 200 companies’ pipelines — including a few overlooked pharma shelves — a new company backed by investment firm Population Health Partners and ARCH Venture Partners is launching with one of the most wide-ranging pipelines yet for obesity drug development. Metsera came out of stealth mode Thursday with $290 million in seed and Series A financing.

Drug Development 321

Drug Development 321

The Guardian - Pharmaceutical Industry

APRIL 18, 2024

Elizabeth Hanna says she was fired by the American Diabetes Association after refusing to approve recipes heaped with the additive made by a major donor Elizabeth Hanna had a simple job: help people with diabetes figure out what to eat. Anyone with common sense knows this should probably not entail foods that might increase people’s risk of getting diabetes.

Diabetes 110

Diabetes 110

STAT

APRIL 18, 2024

These days, the surefire way to get ahead in health insurance is to become a health care provider, and Elevance just upped the ante. It’s joining with private equity to launch a $4 billion primary care company. Elevance leaders divulged more about the company’s venture with Clayton, Dubilier & Rice on its first quarter earnings call Thursday.

314

314

Express Pharma

APRIL 18, 2024

Semaglutide (gOzempic), which is used to improve glycemic control in adults with type-2 diabetes Biocon announced the signing of an exclusive licensing and supply agreement with Biomm S.A., a specialty pharmaceutical company in Brazil, for the commercialisation of its vertically integrated drug product, Semaglutide (gOzempic), which is used to improve glycemic control in adults with type-2 diabetes.

Diabetes 101

Diabetes Biosimilars Pharmaceutical Companies Pharmaceutical Companies 101

STAT

APRIL 18, 2024

WASHINGTON — In the photo, the two men are grinning widely: the CEO of WuXi Biologics and the incoming CEO of the biotechnology industry’s largest trade group. The photo, posted to WuXi’s LinkedIn page , shows the pair in a firm, congratulatory glad hand over John Crowley’s appointment to lead the Biotechnology Innovation Organization.

299

299

Pharmaceutical Technology

APRIL 18, 2024

Inflammation, cell metabolism and neuronal health are current key areas of focus for dementia researchers, according to Jane Osbourn, chief scientific officer (CSO) at Alchemab.

98

98

STAT

APRIL 18, 2024

Rise and shine, everyone, another busy day is on the way. Sadly, gray skies are hovering over the Pharmalot campus again, but our spirits remain sunny, nonetheless. Why? We recall a bit of insight from the Morning Mayor, who taught us that “Every new day should be unwrapped like a precious gift.” To celebrate the notion, we are brewing still more cups of stimulation and inviting you to join us.

276

276

European Pharmaceutical Review

APRIL 18, 2024

New trial results for GSK’s oral gepotidacin, a potential first-in-class oral antibiotic, has shown that it was non-inferior with 92.6 percent success rates in patients with uncomplicated urogenital gonorrhoea (GC). “These results highlight the potential of gepotidacin as a new oral treatment option given the rising incidence of gonorrhoea worldwide” In the pivotal EAGLE-1 Phase III trial, comparatively, intramuscular ceftriaxone (500mg) plus oral azithromycin (1,000mg) combined therapy, a

97

97

STAT

APRIL 18, 2024

How does a startup compete with the likes of Eli Lilly and Novo Nordisk in the rapidly evolving field of weight loss drugs? And how did a major telemedicine company fall flat after its pandemic-induced rise? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We bring on biotech veteran Clive Meanwell to discuss his new obesity startup, Metsera, and running head-to-head trials against Wegovy and Zepbound.

262

262

Pharma Times

APRIL 18, 2024

The Tyche model could help clinicians and researchers capture crucial information in images

Hospitals 127

Hospitals 127

STAT

APRIL 18, 2024

You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine.  Sign up here  to receive it in your inbox on Tuesdays and Thursdays. China tension tests new BIO CEO When John Crowley took over as BIO’s CEO, all was fine and dandy with WuXi AppTec, which was then a member of the trade group.

261

261

pharmaphorum

APRIL 18, 2024

Ireland makes the case for its role as Europe's medtech hotspot, helping companies tackle emerging challenges like digitalisation and sustainability.

102

102

STAT

APRIL 18, 2024

This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox. Good morning! This is a magical time of the year in Boston, with trees in full bloom. I want to hear from you! Send me email at  BiotechScorecard@statnews. com.

254

254

pharmaphorum

APRIL 18, 2024

New obesity biotech Metsera formally launches, led by Clive Meanwell and with a $290m warchest to take on the likes of Novo Nordisk and Eli Lilly.

105

105

BioPharma Dive

APRIL 18, 2024

Company head Anne Wojcicki is considering buying all outstanding shares of the DNA testing firm, which has seen its stock slump in recent years.

103

103

pharmaphorum

APRIL 18, 2024

A gene therapy for heart failure being developed by Bayer’s AskBio unit has been granted fast-track status by the FDA.

114

114

Orsini Pharmacy

APRIL 18, 2024

ELK GROVE VILLAGE, Ill. , April 18, 2024 /PRNewswire/ -- Orsini Specialty Pharmacy has been selected by Edenbridge Pharmaceuticals as the preferred specialty pharmacy partner for the distribution of Yargesa (miglustat) capsules, 100mg. YARGESA is a glucosylceramide synthase inhibitor indicated for the treatment of adult patients with Type 1 Gaucher disease for whom enzyme replacement therapy is not a therapeutic option.

Specialty Pharmacies 90

Specialty Pharmacies 90

Express Pharma

APRIL 18, 2024

ENTOD Pharmaceuticals received approval from CDSCO for PresVu, a treatment for presbyopia, by the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO). PresVu is a eye drop in India designed to alleviate the need for reading glasses among individuals grappling with presbyopia. Presbyopia, characterised by blurred near vision due to the decreased flexibility of the eye’s natural lens, primarily impacts individuals aged 40 and above.

88

88